Komori
Other Disclosures130AVeritas In Silico Inc.Pharmaceuticals

Notice of the Completion of the Relocation of the New Kawasaki Research Institute and the Opening of the Kawasaki Research Institute

The relocation and facility upgrades for the Shin-Kawasaki Research Institute have been completed, and research activities began in April under the name Kawasaki Research Institute. The new facility is located near JR Kawasaki Station, and its laboratory area has increased to approximately four times the previous size.

Worth reading
49Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
4
Laboratory area compared with the previous facility (approximately 4 times)
Wording
Definitive
How definitive the wording is.

Announced details

Kawasaki Research CenterDrug Discovery Platform ibVIS®AI Drug Discovery Platform aibVIS
Applicable field (uses covered by this announcement)

Research on fragile RNA, joint drug discovery research for mRNA-targeted small-molecule pharmaceuticals, and internal pipeline development

Launch dateApril 2026 (actual)
What the company reported numerically
Quantitative Effects

Laboratory area increased to approximately 4 times the previous size

Location (as indicated in this announcement)

66-2 Horikawacho, Saiwai-ku, Kawasaki, Kanagawa Prefecture, Kowa Kawasaki Nishiguchi Building

Laboratory area approximately 4 times the previous size
Impact on Business Performance

Relocation costs have been incorporated into the earnings forecast for the fiscal year ending December 2026, and no material impact requiring special mention is expected to arise on the Company's financial position or operating results going forward.

The company does not address Contract Value / Offering price.

Announced details
ItemDetails
Names of Products / Services CoveredKawasaki Research Center, Drug Discovery Platform ibVIS®, AI Drug Discovery Platform aibVIS
Launch dateApril 2026 (actual)
Applicable areaResearch on fragile RNA, joint drug discovery research for mRNA-targeted small-molecule pharmaceuticals, and internal pipeline development
Location66-2 Horikawacho, Saiwai-ku, Kawasaki, Kanagawa Prefecture, Kowa Kawasaki Nishiguchi Building
Location scaleLaboratory area approximately 4 times the previous size
Quantitative EffectsLaboratory area increased to approximately 4 times the previous size
Impact on Business PerformanceRelocation costs have been incorporated into the earnings forecast for the fiscal year ending December 2026, and no material impact requiring special mention is expected to arise on the Company's financial position or operating results going forward.
Items this document does not state (11)
CounterpartyCounterparty overviewRelationship with the CompanyContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateUsage historySource

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The number of joint drug discovery research projects and internal pipeline development projects has been increasing. The research facility is being expanded to accommodate the use of AI, an increase in research personnel and the renewal of research equipment.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of the Completion of the Relocation of the New Kawasaki Research Institute and the Opening of the Kawasaki Research Institute | Veritas In Silico Inc. (130A) timely disclosure | Komori